AgomAb Therapeutics N.V. American Depositary Shares Accounts Payable

AgomAb Therapeutics N.V. American Depositary Shares's accounts payable stands at $12M as of June 2026. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Open the history chart to see whether AgomAb Therapeutics N.V. American Depositary Shares's accounts payable is expanding or contracting. Sustained growth in accounts payable can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how AgomAb Therapeutics N.V. American Depositary Shares's accounts payable evolved across reporting periods, while the comparison chart places AGMB next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, accounts payable is commonly used to spot outliers. AgomAb Therapeutics N.V. American Depositary Shares's reading of $12M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.